Resistance to Targeted Anti-Cancer Therapeutics

Resistance to Immunotherapeutic Antibodies in Cancer

Strategies to Overcome Resistance

Editors: Bonavida, Benjamin (Ed.)

Free Preview
  • Summarizes common and unique features of mAbs against various cancers
  • Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs
  • Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance
see more benefits

Buy this book

eBook 117,69 €
price for Spain (gross)
  • ISBN 978-1-4614-7654-2
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 176,79 €
price for Spain (gross)
  • ISBN 978-1-4614-7653-5
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
Softcover 145,78 €
price for Spain (gross)
  • ISBN 978-1-4899-8732-7
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
About this book

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

About the authors

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Table of contents (10 chapters)

Table of contents (10 chapters)
  • Resistance to Anticancer Antibodies: From Mechanisms to Solutions

    Pages 1-24

    Reslan, Lina (et al.)

  • Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence

    Pages 25-47

    Wang, Yangyang (et al.)

  • Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors

    Pages 49-71

    Williams, Emily L. (et al.)

  • Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance

    Pages 73-92

    Hernandez-Ilizaliturri, Francisco J. (et al.)

  • Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype

    Pages 93-124

    Bonavida, Benjamin

Buy this book

eBook 117,69 €
price for Spain (gross)
  • ISBN 978-1-4614-7654-2
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 176,79 €
price for Spain (gross)
  • ISBN 978-1-4614-7653-5
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
Softcover 145,78 €
price for Spain (gross)
  • ISBN 978-1-4899-8732-7
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
Loading...

Bibliographic Information

Bibliographic Information
Book Title
Resistance to Immunotherapeutic Antibodies in Cancer
Book Subtitle
Strategies to Overcome Resistance
Editors
  • Benjamin Bonavida
Series Title
Resistance to Targeted Anti-Cancer Therapeutics
Series Volume
2
Copyright
2013
Publisher
Springer-Verlag New York
Copyright Holder
Springer Science+Business Media New York
eBook ISBN
978-1-4614-7654-2
DOI
10.1007/978-1-4614-7654-2
Hardcover ISBN
978-1-4614-7653-5
Softcover ISBN
978-1-4899-8732-7
Series ISSN
2196-5501
Edition Number
1
Number of Pages
XIII, 202
Topics